An interventional study of Radiofrequency and manual tecniques and Manual tecniques in COVID-19, Respiratory Disease and Dyspnea, sponsored by Clinica Gema Leon. Completed at 1 site in Spain. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by Clinica Gema Leon · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 401 studies in COVID-19 with a site in Spain — 25 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · Spain.
Among the 401 studies in COVID-19 with a site in Spain, this one is the 151st largest by enrollment of the 254 interventional ones that give a count, is one of 107 that started in 2021, is one of 85 with no phase, and was the 399th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →25 of the 401 studies in COVID-19 with a site in Spain are open now. Recruiting first, the newest first:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Sites in Spain
Ages 18+
Pfizer · Sites in Spain, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Spain, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Spain, United States, Argentina and 21 more countries
Ages 18+
PEACHES BIOTECH · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
401 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 84 · Phase 3 90 · Phase 4 14
First in 2015; this study’s year is marked. 107 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is close to the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 132 across the 254 interventional studies, 600 across the 146 observational. Of the 287 that completed or were terminated, 73 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 401 have an industry lead sponsor. The 10 most frequent:
Clinica Gema Leon is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Clinica Gema Leon has 4 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
8 of the studies in COVID-19 with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06544395Clinica Gema LeonEfficacy of Non-invasive Neuromodulation Treatments for COVID-19 Sequelae | 2026-12-01 |
| NCT07197164Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSafety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients | 2026-12-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 401 studies in COVID-19 with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The sequelae that occur in post-COVID-19 patients are multiple and, at a therapeutic level, these represent a new challenge within the general context of the pandemic that the world is suffering.
The virus has managed to end thousands of lives today and many other cases are being charged as directly responsible for a multiplicity of multisystem damages that need to be diagnosed and treated. Among the most relevant, are those that can affect to respiratory levels in patients without previous pahologies, and in patients at risk who already had a pathology prior to infection.
On the other hand, signs and symptoms have been observed characteristic in the organ systems described above in post-contagion patients, directly associated with sequelae SARV-CoV2. The radiofrequency (RF) of electromagnetic waves represents a technology of proven efficacy and safety in multiple fields of both human and veterinary medicine.
These include neurological pathologies, respiratory disease and very especially those that affect the locomotor system. In therapeutics there are different RF modalities depending on the modality, polarity, type of signal and frequency, which in turn translate into different therapeutic profiles, clinical indications, efficacy and safety.
Among the RF technologies most used today and that have a greater scientific background, is the one known as Resistive Capacitive Monopolar RadioFrequency at 448 kHz (INDIBA®) (RFMCR). This study aims to assess the efficacy and safety of RFMCR in the treatment of respiratory sequelae in patients presenting this type of pathologies that appear after contagion by COVID-19. Through this non-invasive technique, the investigators want to show that RF can help the physical rehabilitation of these patients through metabolic stimulation, increased vascularization and oxygenation of directly affected tissues, effects of deep hyperthermia generated by the interaction of the current with the treated biological substrate, as well as the activationof tissue regeneration, the result of subthermal action. It is thus intended to improve signs such as lung capacity, dyspnea, neuropathies and global muscle capacity, which are essential for the recovery of the post-COVID-19 patients.
The hypothesis of this study is that current post-COVID-19 treatments can be significantly improved in order to prevent complications and ensure the patients' well-being.
The new post-pandemic era has left sequelae in patients who presented the signs and symptoms of SARS-CoV-2 and subsequently faced a positive for COVID-19. Such sequelae will be evident at various systemic levels of the affected patienta in the short, medium and long term future. One of these levels is respiratory complications and injuries that have been documented throughout all scientific research since the beginning of passive infections worldwide.
SARS-CoV-2 is transmitted by penetrating the respiratory route (mostly), by fluid contact, and to a lesser extent, through the ocular pathway. In the field of neurology system, different forms of RF, nerve infiltrations, lymph node injuries, plantar fasciitis, spinal (peripheral) nerve disorders, etc. have been documented.
If the investigators focus on one of the most prevalent symptoms (those that affect the respiratory system), the bibliography that endorses that the RFMCR could improve has been referenced.
The aim of this study is to evaluate the efficacy of combined manual therapy and 448 kHz radiofrequency treatment in the recovery of lung capacity in patients with post-COVID-19 sequelae. The work proposed here aims to demonstrate the advantages of establishing RF as an excellent treatment for post-COVID-19 sequelae, due to its ability to reinforce immune action, modulate the inflammatory response and activate cellular and tissue regeneration.
The specific objectives of this research work are:
1. To analyze the evolution of lung capacity using an espirometry in patients treated with the combined protocol.
2. To evaluate the improvement in dysnea and tough 3. To determine the impact of treatment on quality of life. 4. To examine the tolerance, safety and possible side effects of the combined treatment in post-COVID-19 patients. REGULATIONS
The principal investigator is responsible for ensuring that this protocol, the informed consent document, and any other information that is presented or facilitated to the possible subjects is reviewed and approved by the CEI. The Researcher agrees to allow direct access to the REC to all relevant documents.
INFORMED CONSENT.
The study patients will give their consent, signing the corresponding model. For this purpose, each informed consent must be signed by both the investigator and the patient.
CONFIDENTIALITY.
FINANCING
It is intended to carry out a longitudinal study with the participation of 96 patients with lung capacity alterations, who confirmed a positive test for COVID-19. The sample size for our study is large enough to detect a clinically important difference in the primary outcome (s). For this, the investigators reviewed references at the bibliographic level, in which paired studies obtained a statistically significant value, being able to support our study.
If the sample size was insufficient but statistically significant, the investigators would resort to expanding the sample.
The participants were divided into three groups:
Each of the participants will be informed of the study, the objective, its possible benefits and the side effects that could arise. A) Therefore, each patient must give their free and confirmed consent through signature. Among the items in the methodology, the following stand out:
Primary outcome: Spirometry was performed at the beginning of the first, sixth, and twelfth sessions, and one and a half months after completing treatment. All spirometry tests were performed in the same manner: the patient was seated with their feet flat on the floor and a nose clip was placed on the patient and they were asked to take two normal breaths, and on the third, to take a maximum inhalation and a maximum exhalation. We obteined the following parameters: FVC (Forced Vital Capacity), FEV1 (Forced Expiratory Volume in 1 Second), FVC/FEV1 (Ratio of FVC to volume expired in 1 second), PEF (Peak Expiratory Flow), PEFT (Peak Expiratory Flow Time), FEF50% (Forced expiratory flow at 50% of expiration), FEF25% - FEF75% (Forced expiratory flow between 25% and 75% of expiration), FEF50%/FIF50 (Ratio of forced expiratory flow at 50% of expiration to forced inspiratory flow at 50% of inspiration) and FEV1/FEV0.5 (Ratio of forced expiratory volume in 1 second to forced expiratory volume in the first 0.5 s)
Secondary outcome: The Sadoul Dyspnea Scale is internationally validated to evaluate the feeling of the patient´sdyspnea and has a 6-grade classification: Grade 0 (No dyspnea), Grade 1 (Dyspnea after significant exertion or climbing two flights of stairs), Grade 2 (Dyspnea when climbing one flight of stairs or with brisk walking on a slight incline), Grade 3 (Dyspnea during brisk walking on level ground), Grade 4 (Dyspnea occurs with slow walking), Grade 5 (Dyspnea with minimal exertion)
Tertiary outcome: Chest measuremnets. All chest measurements, were taken at the first and last measurement sessions, following the same protocol. These measurements were taken with the subject standing in a neutral position and at three different levels, using the following reference points at each level: the axillary line, the tip of the xiphoid bone, and the level of the tenth rib. In addition, three measurements were taken at each level at maximum inspiration, maximum expiration, and neutral.
The therapeutic protocol will be executed in the facilities of the Gema León Physiotherapy and Rehabilitation Clinic (Cordoba, Spain). Depending on the group of treatments the protocol will consist in:
PHASE 1: With the patient in the supine position, treatment was performed along the diaphragm for 10 minutes, of which 5 minutes were spent with the capacitive electrode and the other 5 minutes with the resistive electrode. The plate was placed on the back at the level of the diaphragm.
PHASE 2: The patient was placed in the lateral decubitus position on their right side and 3 minutes were spent with the capacitive electrode and 7 minutes with the resistive electrode. The patient was asked to breathe costal-diaphragmatically throughout the entire duration of the resistive electrode. The plate was placed on the right side, at lung level.
PHASE 3: The same procedure was performed as in the second phase, only this time on the contralateral side.
Such RF therapeutic protocol will be implemented by application with an INDIBA® Activ device, whose function is to reduce inflammation, stimulate immunity and promote tissue regeneration. This will consist of a 45-minute treatment. A total of 12 sessions will be scheduled (two per week), and all processes will be documented from the beginning of therapy (the resources used will be provided by INDIBA and the Gema León Physiotherapy and Rehabilitation Clinic, whose supervision will be carried out by the direction of both).
Another variables which they are gonna be take into account are sex, age, weight, height, smoker, vaccination, number of days with symptoms and type of symptom.
The statistical analysis is based on variables of nominal type mostly, which are suitable for the Chi square test with a significance value of 95% for the results (p \<0.05). However, if there are numerical data that must be compared between groups, the analysis will be used for ANOVA test with the same significance value for the comparison between results.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The radiofrequency is turn off during the treatment
Other: Placebo
Manual tecniques are applied to improve lung capacity
Other: Manual tecniques
Manual tecniques and radiofrequency are applied to improve lung capacity
Other: Radiofrequency and manual tecniques
We apply manual tecniques while we use the radiofrequency, the treatment is divided into 3 phases: * PHASE 1: With the patient in the supine position, treatment was performed along the diaphragm for 10 minutes, of which 5 minutes were spent with the capacitive electrode and the other 5 minutes with the resistive electrode. The plate was placed on the back at the level of the diaphragm. * PHASE 2: The patient was placed in the lateral decubitus position on their right side and 3 minutes were spent with the capacitive electrode and 7 minutes with the resistive electrode. The patient was asked to breathe costal-diaphragmatically throughout the entire duration of the resistive electrode. The plate was placed on the right side, at lung level. * PHASE 3: The same procedure was performed as in the second phase, only this time on the contralateral side, i.e., on the left side.
Manual techniques are used to increase inspiratory capacity, working on the diaphragm and rib cage to increase their mobility along with breathing exercises.
The radiofrequency is turn off
Spirometry
spirometry tests were performed in the same manner: the patient was seated with their feet flat on the floor and a nose clip was placed on the patient and they were asked to take two normal breaths, and on the third, to take a maximum inhalation and a maximum exhalation. We obteined the following parameters: FVC (Forced Vital Capacity), FEV1 (Forced Expiratory Volume in 1 Second), FVC/FEV1 (Ratio of FVC to volume expired in 1 second), PEF (Peak Expiratory Flow), PEFT (Peak Expiratory Flow Time), FEF50% (Forced expiratory flow at 50% of expiration), FEF25% - FEF75% (Forced expiratory flow between 25% and 75% of expiration), FEF50%/FIF50 (Ratio of forced expiratory flow at 50% of expiration to forced inspiratory flow at 50% of inspiration) and FEV1/FEV0.5 (Ratio of forced expiratory volume in 1 second to forced expiratory volume in the first 0.5 s
Time frame: 3 months
Sadoul Dyspnea Scale
The Sadoul Dyspnea Scale is internationally validated to evaluate the feeling of the patient´sdyspnea and has a 6-grade classification: Grade 0 (No dyspnea), Grade 1 (Dyspnea after significant exertion or climbing two flights of stairs), Grade 2 (Dyspnea when climbing one flight of stairs or with brisk walking on a slight incline), Grade 3 (Dyspnea during brisk walking on level ground), Grade 4 (Dyspnea occurs with slow walking), Grade 5 (Dyspnea with minimal exertion)
Time frame: 3 months
Leiscester Test
It is a questionnaire used to objectively assess chronic cough and its effect on quality of life. It is structured into three domains: physical, psychological, and social.
Time frame: 3 months
Chest measurements
All chest measurements, were taken at the first and last measurement sessions, following the same protocol. These measurements were taken with the subject standing in a neutral position and at three different levels, using the following reference points at each level: the axillary line, the tip of the xiphoid bone, and the level of the tenth rib. In addition, three measurements were taken at each level at maximum inspiration, maximum expiration, and neutral.
Time frame: 3 months
Plan to share: No — The request for the data will be studied and considered upon prior and justified request
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Jun 2022, 12 months.
Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 12 months is above that.
Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinica Gema Leon